ProCE Banner Activity

DESTINY-Breast01: Phase II Study of Trastuzumab Deruxtecan (DS-8201a) in HER2+ Advanced Breast Cancer Previously Treated With T-DM1

Slideset Download
Conference Coverage
In patients with HER2+ unresectable or metastatic breast cancer who were previously treated with T-DM1, trastuzumab deruxtecan achieved strong, durable benefit.

Released: December 18, 2019

Expiration: December 16, 2020

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Daiichi Sankyo, Inc.

Genentech TEXT Only

Merck Sharp & Dohme Corp.

Puma Biotechnology, Inc.

Seagen